Ranolazine versus placebo in patients with ischemic cardiomyopathy and persistent chest pain or dyspnea despite optimal medical and revascularization therapy: Randomized, double-blind crossover pilot study

Therapeutics and Clinical Risk Management

Volumn 11, Issue , 2015, Pages 469-474

  Shammas, Nicolas W ^a   Shammas, Gail A ^a   Keyes, Kathleen ^b   Duske, Shawna ^a   Kelly, Ryan ^a   Jerin, Michael ^c  

^a MIDWEST CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^b Cardiovascular Medicine Davenport   (United States)

^c ST AMBROSE UNIVERSITY   (United States)

Author keywords

Angina; Controlled study; Ischemic heart disease; Microvascular disease; Reduced ejection fraction

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANGINA PECTORIS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; RANOLAZINE;

AGED; ARTICLE; CARDIOVASCULAR DISEASE ASSESSMENT; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HEADACHE; HEART EJECTION FRACTION; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPOTENSION; ISCHEMIC CARDIOMYOPATHY; MALE; NAUSEA; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PERSISTENT CHEST PAIN; PILOT STUDY; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE ASSESSMENT; ROSE DYSPNEA SCALE; SEATTLE ANGINA QUESTIONNAIRE; THORAX PAIN;

EID: 84928156724     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S82288     Document Type: Article

References (12)

1. Mentz RJ, Fiuzat M, Shaw LK, et al. Comparison of clinical characteristics and long-term outcomes of patients with ischemic cardiomyopathy with versus without angina pectoris (from the Duke Databank for Cardiovascular Disease). Am J Cardiol. 2012;109(9):1272–1277.
2. Levine TB, Levine AB, Vincenzi A, Keteyian SJ, Billings J, Lesch M. Response of symptomatic myocardial ischemia in ischemic cardio-myopathy to intensive vasodilator therapy. Am J Cardiol. 1997;80(2): 212–214.
3. Pasternac A, Noble J, Streulens Y, Elie R, Henschke C, Bourassa MG. Pathophysiology of chest pain in patients with cardiomyopathies and normal coronary arteries. Circulation. 1982;654:778–789.
4. Chaitman BR, Skettino SL, Parker JO, et al; MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazine mono-therapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43(8):1375–1382.
5. Chaitman BR, Pepine CJ, Parker JO, et al; Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291(3):309–316.
6. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Skene A, McCabe CH, Braunwald E; MERLIN-TIMI 36 Investigators. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Effciency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am Heart J. 2006;151(6):1186.e1–1186.e9.
7. Spertus JA, Jones P, McDonell M, Fan V, Fihn SD. Health status predicts long-term outcome in outpatients with coronary disease. Circulation. 2002;106(1):43–49.
8. Rose GA, Blackburn H. Cardiovascular survey methods. Monogr Ser World Health Organ. 1968;56:1–188.
9. Belardinelli L, Antzelevitch C, Fraser H. Inhibition of late (sustained/ persistent) sodium current: a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on car-diomyocyte function. Eur Heart J Suppl. 2004;6(Suppl 1):S13–S17.
10. Pieske B, Maier LS, Piacentino V, Weisser J, Hasenfuss G, Houser S. Rate dependence of [Na+]i and contractility in nonfailing and failing human myocardium. Circulation. 2002;106(4):447–453.
11. Wagner S, Dybkova N, Rasenack EC, et al. Ca2+/calmodulin-dependent protein kinase II regulates cardiac Na+ channels. J Clin Invest. 2006; 116(12):3127–3138.
12. Fihn SD, Gardin JM, Abrams J, et al; American College of Cardiology Foundation/American Heart Association Task Force. 2012 ACCF/ AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126(25):e354–e471.